Send a Tweet
Most Popular Choices
Share on Facebook 29 Share on Twitter Printer Friendly Page More Sharing
Sci Tech    H3'ed 12/10/20

We Had the COVID-19 Vaccine the Whole Time

Quicklink Submitted By   2 comments
Become a Premium Member Would you like to know how many people have read this article? Or how reputable the author is? Simply sign up for a Advocate premium membership and you'll automatically see this data on every article. Plus a lot more, too.
Author 7804
Follow Me on Twitter     Message molly cruz
Become a Fan
  (15 fans)

You may be surprised to learn that of the trio of long-awaited coronavirus vaccines, the most promising, Moderna’s mRNA-1273, which reported a 94.5 percent efficacy rate on November 16, had been designed by January 13.

To be clear, I don’t want to suggest that Moderna should have been allowed to roll out its vaccine in February or even in May, when interim results from its Phase I trial demonstrated its basic safety. “That would be like saying we put a man on the moon and then asking the very same day, ‘What about going to Mars?’ ” says Nicholas Christakis, who directs Yale’s Human Nature Lab and whose new book, Apollo’s Arrow, sketches the way COVID-19 may shape our near-term future. Moderna’s speed was “astonishing,” Christakis says, though the design of other vaccines was nearly as fast: BioNTech with Pfizer, Johnson & Johnson, AstraZeneca.

Read the rest of the story HERE:

At nymag.com

 

Rate It | View Ratings

molly cruz Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Born in Long Island public school year in Sweden as exchange student, went to Harvard one year, Cooper Union in NYC as Art student. Have two children, one of whom is rock mogul, the other has three daughters, one of whom has two daughters, making me (more...)
 
Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
Name
Email
   (Opens new browser window)
 

To View Comments or Join the Conversation: